Natera, Inc. (NTRA)

Market Cap	6.42B
Revenue (ttm)	820.22M
Net Income (ttm)	-547.80M
Shares Out	113.29M
EPS (ttm)	-5.57
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	929,530
Open	55.09
Previous Close	55.70
Day's Range	54.32 - 56.72
52-Week Range	27.35 - 59.75
Beta	1.20
Analysts	Buy
Price Target	76.14 (+34.4%)
Earnings Date	May 4, 2023

About NTRA

Natera, Inc., a diagnostics company, develops and commercializes molecular testing services worldwide. It offers Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus with a blood draw from the mother, as well as twin pregnancies for zygosity; Vistara, a single-gene mutations screening test to identify single-gene disorder; Horizon carrier screening to determine carrier status for various genetic diseases; and Spectrum to identify chromosomal anomalies or inherited genetic conditions during an in vitro fer...

• Industry: Diagnostics & Research
• Sector: Healthcare
• IPO Date: Jul 2, 2015
• Employees: 2,670
• Stock Exchange: NASDAQ
• Ticker Symbol: NTRA

Financial Performance

In 2022, Natera's revenue was $820.22 million, an increase of 31.13% compared to the previous year's $625.49 million. Losses were -$547.80 million, 16.1% more than in 2021.

Analyst Forecast

According to 20 analysts, the average rating for NTRA stock is "Buy." The 12-month stock price forecast is $76.14, which is an increase of 34.40% from the latest price.

Price Target

$76.14

(34.40% upside)

Analyst Consensus: Buy